OBJECTIVES:Ketamine, an N-methyl d-aspartate (NMDA) antagonist, has rapid antidepressant effects in depressed subjects with bipolar disorder (BD). Evidence supports a role for the glutamatergic system in the pathophysiology of BD. This double-blind, randomized, cross-over study sought to determine cerebral metabolic correlates of antidepressant response to ketamine. METHODS:Twenty-one subjects with BD currently in a depressed state underwent [(18) F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging after receiving a placebo infusion as well as after receiving a ketamine infusion. Metabolism was compared between ketamine and placebo infusions, and correlated with clinical response. Regional metabolic rate of glucose (rMRGlu) in regions of interest (ROIs) and Montgomery-Åsberg Depression Rating Scale (MADRS) scores were the main outcome measures. RESULTS: The study found that change in metabolism between sessions was significantly correlated with percentage change in MADRS scores in the right ventral striatum; subjects who showed the greatest improvement had the largest metabolic increase after ketamine infusion compared to placebo. In a voxel-wise analysis, subjects with BD had significantly lower glucose metabolism in the left hippocampus following the ketamine infusion than following the placebo infusion. In addition, metabolism in the subgenual anterior cingulate cortex (ACC) following the placebo infusion was positively correlated with percentage improvement in MADRS score following the ketamine infusion. CONCLUSIONS: Taken together, the results suggest that higher activity in the subgenual ACC may predict antidepressant response to ketamine. Ketamine administration altered glucose metabolism in areas known to be involved in mood disorders; these alterations may partially underlie ketamine's mechanism of action. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
RCT Entities:
OBJECTIVES:Ketamine, an N-methyl d-aspartate (NMDA) antagonist, has rapid antidepressant effects in depressed subjects with bipolar disorder (BD). Evidence supports a role for the glutamatergic system in the pathophysiology of BD. This double-blind, randomized, cross-over study sought to determine cerebral metabolic correlates of antidepressant response to ketamine. METHODS: Twenty-one subjects with BD currently in a depressed state underwent [(18) F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging after receiving a placebo infusion as well as after receiving a ketamine infusion. Metabolism was compared between ketamine and placebo infusions, and correlated with clinical response. Regional metabolic rate of glucose (rMRGlu) in regions of interest (ROIs) and Montgomery-Åsberg Depression Rating Scale (MADRS) scores were the main outcome measures. RESULTS: The study found that change in metabolism between sessions was significantly correlated with percentage change in MADRS scores in the right ventral striatum; subjects who showed the greatest improvement had the largest metabolic increase after ketamine infusion compared to placebo. In a voxel-wise analysis, subjects with BD had significantly lower glucose metabolism in the left hippocampus following the ketamine infusion than following the placebo infusion. In addition, metabolism in the subgenual anterior cingulate cortex (ACC) following the placebo infusion was positively correlated with percentage improvement in MADRS score following the ketamine infusion. CONCLUSIONS: Taken together, the results suggest that higher activity in the subgenual ACC may predict antidepressant response to ketamine. Ketamine administration altered glucose metabolism in areas known to be involved in mood disorders; these alterations may partially underlie ketamine's mechanism of action. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Lawrence S Kegeles; Diana Martinez; Lisa D Kochan; Dah-Ren Hwang; Yiyun Huang; Osama Mawlawi; R F Suckow; Ronald L Van Heertum; Marc Laruelle Journal: Synapse Date: 2002-01 Impact factor: 2.562
Authors: Carlos A Zarate; Nancy E Brutsche; Lobna Ibrahim; Jose Franco-Chaves; Nancy Diazgranados; Anibal Cravchik; Jessica Selter; Craig A Marquardt; Victoria Liberty; David A Luckenbaugh Journal: Biol Psychiatry Date: 2012-01-31 Impact factor: 13.382
Authors: E Mundo; S Tharmalingham; M Neves-Pereira; E J Dalton; F Macciardi; S V Parikh; A Bolonna; R W Kerwin; M J Arranz; A J Makoff; J L Kennedy Journal: Mol Psychiatry Date: 2003-02 Impact factor: 15.992
Authors: David F Moore; Gheona Altarescu; W Craig Barker; Nicholas J Patronas; Peter Herscovitch; Raphael Schiffmann Journal: Brain Res Bull Date: 2003-12-30 Impact factor: 4.077
Authors: B G Bunney; J Z Li; D M Walsh; R Stein; M P Vawter; P Cartagena; J D Barchas; A F Schatzberg; R M Myers; S J Watson; H Akil; W E Bunney Journal: Mol Psychiatry Date: 2014-11-04 Impact factor: 15.992
Authors: Dawn F Ionescu; Julia M Felicione; Aishwarya Gosai; Cristina Cusin; Philip Shin; Benjamin G Shapero; Thilo Deckersbach Journal: Harv Rev Psychiatry Date: 2018 Nov/Dec Impact factor: 3.732
Authors: Robin Ortiz; Mark J Niciu; Nada Lukkahati; Leorey N Saligan; Allison C Nugent; David A Luckenbaugh; Rodrigo Machado-Vieira; Carlos A Zarate Journal: J Affect Disord Date: 2014-10-16 Impact factor: 4.839
Authors: Marc S Lener; Mark J Niciu; Elizabeth D Ballard; Minkyung Park; Lawrence T Park; Allison C Nugent; Carlos A Zarate Journal: Biol Psychiatry Date: 2016-05-12 Impact factor: 13.382